William J. Steinbach

High Impact

Chair and Associate Dean

University of Arkansas for Medical Sciences

faculty

Pediatrics, College of Medicine

68 h-index 287 pubs 26,515 cited

Research Areas

Links

ORCID Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

William J. Steinbach leads a multidisciplinary clinical care and research program focused on immunosuppressed children, with a primary emphasis on the pathogenesis, diagnosis, and treatment of invasive fungal infections. His work also encompasses broader efforts related to all infections in immunocompromised patients. For over a decade, Steinbach has consistently served as Principal Investigator on multiple concurrent NIH R01 awards and has contributed to T32 awards in molecular mycology and pediatric infectious diseases. He has also been an active member of numerous national scientific and research advisory panels.

Prior to his current roles as Chair and Associate Dean of Pediatrics at the University of Arkansas for Medical Sciences and Pediatrician-in-Chief at Arkansas Children's, Steinbach held significant positions at Duke University, including Samuel L. Katz Distinguished Professor of Pediatrics and Vice Chair of Research. His academic contributions are reflected in a substantial publication record, with 287 total publications, 26,515 total citations, and an h-index of 68. He is recognized as a highly cited researcher.

Steinbach's research group has investigated various aspects of pediatric infectious diseases, including the safety and pharmacokinetics of antifungal medications in pediatric patients, comparative effectiveness of different antifungal treatments for invasive candidiasis, and the development of novel antifungal agents. His work also extends to policy statements on antibiotic stewardship in pediatrics and research on COVID-19 vaccines in children and adolescents.

Metrics

h-index: 68
Publications: 287
Citations: 26,515

Selected Publications

Drugs for Parasitic Infections (2025) DOI
Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi (2024) DOI
Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network (2024) DOI
Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi (2024) DOI
Fecal Microbiota Transplantation: Information for the Pediatrician (2023) DOI
Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal (2023) DOI
Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22-modified FK520 analog against C. neoformans (2023) DOI
Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network (2023) DOI
Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22 modified FK520 analog against C. neoformans (2023) DOI
American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients (2023) DOI
Calcineurin Inhibitor CN585 Exhibits Off-Target Effects in the Human Fungal Pathogen Aspergillus fumigatus (2022) DOI
Prospective Evaluation of the Fungitell® (1→3) <scp>Beta‐D‐Glucan</scp> Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children's Oncology Group (2022) DOI